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Abstract
OBJECTIVE: To determine the effects of human um-
bilical cord mesenchymal stem cell (UCMSC) trans-
plantation, alone or in combination with tanshi-
none IIA (Tan IIA) on hepatic cirrhosis in rats.
METHODS: A rat model of cirrhosis was estab-
lished. Rats were divided into control, UCMSC, and
UCSMC plus Tan IIA groups. Rats in the UCMSC
group were injected via the tail vein with 0.2 mL
DiI-labeled UCMSC suspension. Intraperitoneal Tan
IIA injections (20 mg/kg) were started on the day of
UCMSC transplantation in the UCMSC plus Tan IIA
group, and continued for 7 consecutive days there-
after. Rats were sacrificed 1 day, 3 days, 1 month,
and 3 months after transplantation and the num-
bers of DiI-labeled UCMSCs colonizing the liver
were determined. Albumin (ALB) and alanine ami-
notransferase (ALT) levels were measured in ve-
nous blood, and mRNA and protein expression lev-
els of human ALB and cytokeratin (CK)-18 in liver
tissues were determined by reverse transcrip-
tion-polymerase chain reaction and western blot-
ting, respectively.
RESULTS: Serum ALT levels were significantly lower
and serum ALB levels significantly higher in rats in
the UCMSC group compared with the control
group (P < 0.05). Hepatic CK-18 and ALB mRNA and
protein expression levels increased after transplan-
tation, and were significantly higher in the UCMSC
plus Tan IIA group compared with the UCMSC
group (P < 0.05).
CONCLUSION: Human UCMSCs transplanted into
rats with liver cirrhosis can grow and differentiate
into hepatocyte-like cells resulting in improved liv-
er function in vivo. Tan IIA further influenced trans-
plantation outcomes.
© 2015 JTCM. All rights reserved.
Key words: Liver cirrhosis; Umbilical cord; Mesen-
chymal stem cells; Tanshinone; Transplantation
INTRODUCTION
Cirrhosis is a major human health problem that con-
sumes social resources.1,2 Treatments for liver cirrhosis
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have been extensively researched, and liver transplanta-
tion has been shown to prolong the survival of patients
with cirrhosis. However, transplantation is expensive,
donors are limited, and the procedure is associated
with ethical issues, all of which seriously limit its clini-
cal application. Biological artificial liver treatment can-
not resolve the underlying pathological process, which
fundamentally decreases the number of functional liver
cells. However, stem cell research may offer a novel
treatment for liver cirrhosis. Various stem cells have
been shown to be useful for liver cell regeneration and
repair.3-7 Although most studies have investigated the
application of bone marrow mesenchymal stem cells
(MSCs),8-13 few human bone marrow MSCs differenti-
ate into liver cells.14 In addition, the acquisition of
bone marrow MSCs increases the morbidity of patients
with liver cirrhosis. Umbilical cord MSCs (UCMSCs)
are capable of multi-directional differentiation,15,16 and
thus also have potential for the treatment of liver cir-
rhosis. UCMSCs exhibit the general characteristics of
stem cells: they have an original phenotype without
spontaneous differentiation, do not express graft-ver-
sus-host disease-associated antigens, possess similar
morphology and immunophenotype, but show lower
proliferation and differentiation abilities than bone
marrow MSCs.17-20
Tanshinone IIA (Tan IIA) is extracted from the fat-sol-
uble component of Danshen (Radix Salviae Miltiorrhi-
zae). It has been shown to relieve pain and promote
blood circulation.21 Tan IIA is a natural antioxidant
with hepatoprotective, anti-fibrosis, and anti-cancer ef-
fects, and has also shown potential for inducing stem
cell proliferation and differentiation.21,22 In this study,
we investigated the effects of UCMSC transplantation,
alone and in combination with Tan IIA, on serum lev-
els of albumin (ALB) and alanine aminotransferase
(ALT), and liver human cytokeratin (CK)-18 and ALB
mRNAandprotein levels in a ratmodel of liver cirrhosis.
MATERIALS ANDMETHODS
Establishment of rat model of liver cirrhosis
Sixty healthy female specefic pathogen free -grade
Sprague-Dawley rats [(280±20) g; 6-8 weeks old] were
obtained from the Experimental Animal Center of
Yangzhou University. The rats were randomly divided
into the following groups: control group (10 rats), in-
traperitoneal injection of physiological saline, 0.75 mL/
kg; and experimental group (50 rats), intraperitoneal
injection of 15% carbon tetrachloride 22 in liquid par-
affin oil, 0.75 mL/kg, three times per week for 8
weeks. All rats were allowed free access to drinking wa-
ter and food. After 8 weeks, four rats were randomly se-
lected from each group and examined for pathological
changes indicative of cirrhosis of the liver.
Human UCMSC transplantation
The cirrhotic rats were divided into three groups: con-
trol group (15 rats); UCMSC group (15 rats); and US-
CMC plus Tan IIA group (15 rats). In the UCMSC
group, 0.2 mL of a suspension containing approximate-
ly 2 × 107 DiI-labeled UCMSCs was injected into the
tail vein. In the UCMSC plus Tan IIA group, intraperi-
toneal Tan IIA (20 mg/kg) injections were started on
the same day as UCMSC transplantation and contin-
ued for 7 consecutive days thereafter. Rats were sacri-
ficed 1 day, 3 days, 1 month, and 3 months after trans-
plantation to measure ALB and ALT levels in venous
blood.
In vitro culture and DiI labeling of human UCMSCs
Umbilical cords were obtained from the Second Affili-
ated Hospital of Nanjing Medical University, after ob-
taining maternal consent. Under aseptic conditions,
fresh umbilical cord cells were separated, inoculated in-
to culture flasks containing T75, and cultured in se-
rum-free medium. A cell suspension was collected in
accordance with the 1∶3 of inoculation, third genera-
tion (P3) of subculture, spare. Cell morphology and
growth were monitored continuously in randomly se-
lected samples of the suspension, and the results were
recorded.
Human UCMSCs were labeled with the intrahepatic
tracer DiI after 24 h, and transplanted into the rats.
One week later, liver colonization by DiI-labeled cells
was confirmed by immunofluorescence examination.
Five sections were obtained from the liver of each rat
in the UCMSC, UCMSC plus Tan II, and control
groups. The numbers of DiI-positive cells were deter-
mined in five high-power fields (magnification, ×100)
in each section, and the average numbers of cells per
high-power field were compared between the groups.
Flow cytometry for surface marker identification
Following enzymatic digestion, passage-3 cells (1 × 106
cells/mL) were treated with TrypLE (Invitrogen, No.
12604021), and then washed twice with phos-
phate-buffered saline (PBS). Aliquots of cells were
transferred to test tubes and incubated with CD14-flu-
oroisothiocyanate (FITC) (Beckmancoulter), CD45-F
ITC (Beckmancoulter), CD79a-allophycocyanin (APC)
(Abcam), CD90-APC (R&D), CD34-phycoerythrin
(PE) (Abcam, ab46925), CD73-PE (Santa Cruz),
CD105-PE (eBioscience), and human leucocyte anti-
gen (HLA)-DR-PE (eBioscience) antibodies at 4 ℃ for
30 min in the dark. Surface markers were detected us-
ing flow cytometry after washing twice with PBS.
FITC-, PE-, and APC-labeled mouse immunoglobulin
isotypes, respectively, were used as negative controls.
Detection of ALB and CK-18 mRNA in liver tissueTotal RNA was extracted from frozen liver tissue using
Trizol, and used for cDNA synthesis by reverse tran-
scription (RT). The cDNA was then used as a template
for polymerase chain reaction (PCR) amplification ac-
cording to the following protocol: degeneration at
94 ℃ for 30 s, annealing at 94 ℃ for 5 s, and exten-
sion at 55 ℃ for 30 s, for 45 cycles. The primer se-
quences are given in Table 1.
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Detection of ALB and CK-18 proteins in liver tissue
Liver tissue 500-600 mg and 1 mL lysed tissue extract
were centrifuged (15000 × g) and the supernatant was
stored at ﹣80 ℃ for Bradford protein assay. We pre-
pared a separation gel (8%) and a stacking gel (4.5%).
The first sample was separated using vertical electro-
phoresis at a voltage of 80 V for 30 min, and then elec-
trophoresed at 110 V for 60 min. The bands were then
electrotransferred to a polyvinylidene fluoride mem-
brane and incubated overnight in buffer containing
5% skim milk powder at 4 ℃. The two corresponding
antibodies were then added and the incubation was
continued for 1 h at room temperature. Electrochemi-
luminescence imaging was performed, using β-actin as
an internal reference.
Histological observation
Rats from each group were dissected at different time
points. Hepatic hilar tissue was fixed in 10% formalin,
embedded in paraffin, sectioned, and subjected to his-
tological examination after staining with hematoxylin
and eosin.
Statistical analyses
All statistical analyses were performed by GraphPad
Prism 5.0 software (GraphPad Software, Inc., San Di-
ego, CA, USA). One way analysis of variancewas used
for comparison of quantitative data between different
groups. Least significant difference was used for fur-
ther multiple comparison. Data are expressed as mean
± standard deviation ( xˉ ± s). A P < 0.05 was considered
to be statistically significant.
RESULTS
Pathological examination
Pathological changes in liver tissues were examined in
control and cirrhotic rats at 8 weeks after the establish-
ment of the model. Liver tissue in control rats (Figure
1A) showed a well-defined architecture. The structure
of the hepatic lobules was clear, the liver cells were ar-
ranged in cords around the central vein, the sinuses
showed a regular structure, the nuclei of the liver cells
were round, and there was no periportal inflammatory
cell infiltration. However, in the experimental group
(Figure 1B), there were widespread false lobules, visible
intrahepatic, false lobular re-segregation of fibers, obvi-
ous nodules of stem cell regeneration, and prominent
inflammatory cell infiltration around the portal area
and central veins.
Human UCMSC culture
After culture and passaging for three generations, hu-
man UCMSCs appeared fusiform and relatively homo-
geneous, and were arranged in parallel or whirl-
pool-like adherent growths (Figure 2). Flow cytometry
after the third passage showed that the cells expressed
high levels of surface markers characteristic of UC-
MSCs, including CD73, CD90, and CD105 (97.2%,
99.7%, and 98.1%, respectively) (Figure 3). The cells
were negative for CD34 (0.2%), CDHLA-DR (0.3%),
CD79a (2%), CD14 (0.3%), and CD45 (0.5%).
Hepatic colonization by DiI-labeled human
UCMSCs
After 24 h, DiI-labeled UCMSCs were seen in the
livers of rats in the UCMSC and UCMSC plus Tan
IIA groups (average UCMSC counts, 25.4 ± 16.6
and 34.8 ± 22.0, respectively), but not in the control
group (Figure 4). No fluorescent protein-labeled cells
Primer
ALB-F
ALB-R
CK-18-F
CK-18-R
Actin-F
Actin-R
Sequence
ACACCCAGAAAGCACCTCAG
AAAGGCAATCAACACCAAGGC
CCGCTACGCCCTACAGAT
GGCATCACCAAGATTAAAGTCC
CATTCCAAATATGAGATGCGTTGT
TGTGGACTTGGGAGAGGACT
Product length (bp)
184
199
103
Table 1 Primer sequences
A B
Figure 1 Establishment of a rat model of hepatic cirrhosis af-
ter 8 weeks (HE ×200)
A: Control group, intraperitoneal injection of physiological
saline, 0.75 mL/kg; B: Experimental group, intraperitoneal in-
jection of 15% carbon tetrachloride 22 in liquid paraffin oil,
0.75 mL/kg, three times per week for 8 weeks, Liver cirrho-
sis model in mice showed that extensive false lobule. HE: he-
matoxylin-eosin.
Figure 2 Adherent growth of
human UCMSCs (DAPI×500)
Human UCMSCs appeared fu-
siform and relatively homoge-
neous, and were arranged in
parallel or whirlpool-like ad-
herent growths. UCMSC: um-
bilical cord mesenchymal
stem cell; DAPI: 4,6-diami-
no-2-phenyl indole.
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were observed in any group at 1 week after transplan-
tation.
Changes in serum ALB and ALT levels after UCSMC
transplantation
There were no obvious changes in serum ALB and
ALT levels in any of the groups at 3 days after trans-
plantation. However, at 1 and 3 months after trans-
plantation, ALT levels were obviously decreased and
ALB levels significantly increased in the UCSMC and
UCMSC plus Tan IIA groups, compared with levels in
the control group (P < 0.05) (Figure 5).
Expression of ALB and CK-18 mRNA and protein
mRNA and protein expression levels of ALB and
CK-18 were significantly higher in the UCSMC and
UCSMC plus Tan IIA groups compared with the con-
trol group, according to RT-PCR and western blot, re-
spectively (P < 0.05) (Figures 6, 7).
DISCUSSION
In this study, we investigated the therapeutic effects of
UCMSC transplantation and Tan IIA injection in a rat
model of liver cirrhosis.
Liver-injury repair is a two-stage process involving the
regeneration of liver cells and hyperplasia of fibrous tis-
sue. Fibrous-tissue hyperplasia is useful during the ear-
ly stage of liver damage, but continued fibrosis results
in the excessive accumulation of extracellular matrix,
and eventually to cirrhosis and liver failure.23-29 The
treatment of liver cirrhosis thus requires an increase in
the number of new liver cells and a decrease in the de-
position of extracellular matrix. In this study, we used a
histologically proven carbon tetrachloride-induced rat
model of cirrhosis. Furthermore, human UCMSCs
had colonized the rat livers 24 h after transplantation
via the tail vein, as confirmed by immunofluorescence
microscopy. Serum ALT levels were significantly lower
and serum ALB levels significantly higher in the trans-
planted rats at 1 and 3 months after transplantation,
compared with the control rats. These results are con-
sistent with Zhang et al,27 who showed that ALB and
CK-18 mRNA and protein were expressed in the livers
of rats transplanted with UCMSCs, and also with Ban-
as et al 30 who showed that UCMSCs could differenti-
ate into liver cells in rats with liver cirrhosis.
Stem-cell homing to a new organ and their differentia-
tion into mature cells of the corresponding tissue can
replace and repair injured tissues. However, increasing
the number of transplanted cells for differentiation re-
mains an important issue in transplantation treatment.
This increase in cell number is currently achieved main-
ly by the application of chemical inducers of differenti-
ation in vitro; however, most chemical inducers have
some degree of toxicity. Recent experiments31-33 have
confirmed the potential of Tan IIA, a monomer isolat-
ed from S. miltiorrhiza, as an inducer of stem cell pro-
CBA
Figure 4 Colonization of rat liver by DiI-labeled human UCMSCs (DiI x100)
A: control group; B: the UCMSC group; C: the number of UCMSCs was significantly higher in the UCMSC plus Tan IIA group. After
24 h, DiI-labeled UCMSCs were seen in the livers of rats in the UCMSC and UCMSC plus Tan IIA groups, but not in the control
group. UCMSC: umbilical cord mesenchymal stem cell.
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Figure 3 Flow cytometric detection of UCMSCs expressing high levels of surface markers
A: CD73 (97.2%); B: CD90 (99.7%); C: CD105 (98.1%). UCMSC: umbilical cord mesenchymal stem cell; PE: phycoerythrin; APC: allo-
phycocyanin.
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liferation and differentiation. Tan IIA has been used in
vitro to induce bone marrow MSCs to differentiate in-
to bone cells and neuron-like cells.
We demonstrated that Tan IIA increased the number
of transplanted UCMSCs colonizing the liver after 24
h, compared with UCMSC transplantation alone.
Moreover, serum ALT levels were significantly lower
and serum ALB levels significantly higher at 1 and 3
months after transplantation, and hepatic ALB and
CK-18 mRNA and protein expression levels were high-
er in transplanted rats treated with Tan IIA, compared
with UCMSCs alone. These results indicate that Tan
IIA can influence the outcomes of human UCMSC
transplantation in rats with liver cirrhosis, but the un-
derlying mechanism remains unclear. Further studies
are needed to determine if Tan IIA can induce the dif-
ferentiation of UCMSCs into hepatocytes.
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